Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ocular Blood Flow Imaging for Glaucoma Assessment

NCT: NCT05726058 · RECRUITING

NCT IDNCT05726058
StatusRECRUITING
Start Date2023-03-30
Completion2028-04-30
SponsorUniversity of Maryland, Baltimore (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: * Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring? Participants will be * measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the XyCAM RI while inhaling 100% oxygen through a mask

Frequently Asked Questions

What is Ocular Blood Flow Imaging for Glaucoma Assessment?

Ocular Blood Flow Imaging for Glaucoma Assessment is a clinical trial registered under NCT05726058. Current status: RECRUITING.

What is the status of NCT05726058?

The current status of NCT05726058 (Ocular Blood Flow Imaging for Glaucoma Assessment) is: RECRUITING.

When did Ocular Blood Flow Imaging for Glaucoma Assessment start?

Ocular Blood Flow Imaging for Glaucoma Assessment started on 2023-03-30.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.